The modeled fair value for Intellia Therapeutics is held at US$25.29 per share, even as Street price targets around US$28, US$29 and US$30 respond to the FDA lifting clinical holds on key MAGNITUDE ...
Coramitug is designed to clear toxic protein deposits from the heart, offering a new approach to treating ATTR cardiomyopathy ...
CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes 1 PALO ALTO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: ...
Prothena Corporation plc (NASDAQ:PRTA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug, a potential best-in-class amyloid depleter ...
As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...
Diagnostic delay was common (277/505) and operationalized as ≥1 inpatient or ≥2 outpatient diagnoses for key ATTR-CM ...
Everyday Health on MSN
Genetic testing and ATTR-CM: Everything you need to know
Learn why genetic testing is vital for ATTR-CM diagnosis, how it identifies hereditary risks for family members, and the benefits of early treatment and counseling.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results